颅内动脉粥样硬化性狭窄的TOF-MRA视觉分级系统的开发与验证
本研究基于132个狭窄段开发并验证了TOF-MRA视觉分级系统MRAVICAST,其总体诊断准确率93.9%(124/132),高于MRAWASID的50.8%(67/132),与DSA参考的狭窄程度无显著差异(p=.849),观察者间一致性ICC为0.989(95%CI 0.979-0.999),对>50%和>70%狭窄的阳性预测值分别为97.3%和100.0%。
要点
- MRAVICAST总体诊断准确率93.9%(124/132),高于MRAWASID的50.8%(67/132)。
- MRAVICAST与DSA参考的狭窄程度无显著差异(p=.849),观察者间一致性ICC为0.989(95%CI 0.979-0.999)。
- 对>50%和>70%狭窄的阳性预测值分别为97.3%和100.0%。
核心结论
- MRAVICAST能准确可靠地判定颅内动脉粥样硬化患者的狭窄程度,可能成为MRAWASID的通用替代方法。
研究设计与样本
- 单中心队列研究,分析2014年1月至2020年2月前瞻性观察性登记数据,纳入71例患者(34男、37女,平均年龄61.0±15.25岁,范围21-89岁)的132个颅内动脉粥样硬化性狭窄段,以DSA为参考标准,开发基于TOF-MRA物理特性的4点评分系统。
诊断标准与关键数值
- MRAVICAST总体诊断准确率为93.9%(124/132),MRAWASID为50.8%(67/132)。
临床应用与阅片要点
- 作者认为MRAVICAST在颅内动脉粥样硬化性狭窄的药物治疗时代可能成为MRAWASID的通用替代方法。
局限性
- 本文要点部分将研究描述为回顾性诊断研究,与摘要中的单中心队列研究及前瞻性观察性登记数据表述不一致。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Although the overestimation problem of time-of-flight magnetic resonance angiography (TOF-MRA) applying the warfarin-aspirin symptomatic intracranial disease (WASID) method to assess intracranial arterial stenosis has often been suggested, no pertinent grading system for TOF-MRA has been developed. We aimed to develop and evaluate the performance of a visual grading system for intracranial arterial stenosis on TOF-MRA (MRAVICAST).
METHODS: This single-center cohort study analyzed prospective observational registry data from a comprehensive stroke center between January 2014 and February 2020. Patients with confirmed stenosis of the intracranial large arteries who underwent confirmative digital subtraction angiography (DSA) were included; a 4-point grading system was developed based on physical characteristics of TOF-MRA. The overall diagnostic accuracies of MRAVICAST for each grade, interobserver reproducibility, and positive predictive values for > 50% and > 70% stenoses were evaluated.
RESULTS: We analyzed 132 segments with intracranial atherosclerotic stenosis from 71 patients (34 men and 37 women; mean age, 61.0 ± 15.25 years; range, 21-89 years). The overall diagnostic accuracy of MRAVICAST (93.9%, 124/132) was higher than that of MRAWASID (50.8%, 67/132) for each grade. The degree of stenosis did not differ significantly between MRAVICAST and DSAWASID (p = .849). Regarding reproducibility, MRAVICAST demonstrated excellent interobserver agreement (ICC, 0.989; 95% CI, 0.979-0.999). The positive predictive values of MRAVICAST for the diagnosis of > 50% and > 70% stenoses were 97.3% and 100.0%, respectively.
CONCLUSIONS: The new intuitive grading system accurately and reliably determined the degree of stenosis in intracranial arterial atherosclerosis patients. MRAVICAST could be a versatile alternative to MRAWASID for evaluating intracranial arterial stenosis.
KEY POINTS: • In this retrospective diagnostic study (sample: 132 stenotic segments), the overall accuracy of the visual grading system (MRAVICAST) was 94%, and positive predictive value for > 50% stenosis was 97%. • In the era of medical treatment for intracranial atherosclerotic stenosis, MRAVICAST could be a versatile alternative method to MRAWASID for evaluating intracranial arterial stenosis.
引用
- You, Kim, Yang, et al. Development and validation of visual grading system for stenosis in intracranial atherosclerotic disease on time-of-flight magnetic resonance angiography. Eur Radiol. 2021. PMID: 34839372. doi:10.1007/s00330-021-08319-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。